The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis
Clinical Cardiology, 05/16/2012Wang P et al.
The triple therapy is associated with a higher level of adverse drug events, including rash (OR: 2.45, 95% CI: 1.41–4.23, P = 0.001), gastrointestinal disorders (OR: 2.59, 95% CI: 1.26–5.30, P = 0.009), and drug discontinuation (OR: 3.80, 95% CI: 1.59–9.10, P = 0.003), but it has no difference in bleeding compared with the dual therapy (OR: 1.05, 95% CI: 0.71–1.55, P = 0.80).
Authors performed a meta–analysis based on 8 randomized controlled trials.
A total of 3332 patients to compare the effectiveness and safety of this triple therapy with traditional dual therapy (aspirin and clopidogrel).
These findings suggested that the triple therapy is more effective than dual therapy in preventing restenosis (odds ratio [OR]: 0.52, 95% confidence interval [CI]: 0.40–0.66, P < 0.00001), maintaining minimal lumen diameter (OR: 0.15, 95% CI: 0.10–0.20, P < 0.00001), and avoiding target–vessel revascularization (OR: 0.62, 95% CI: 0.47–0.82, P = 0.001).
There is also no significant difference in major adverse cardiac and cerebrovascular events between the 2 therapies, except the smaller occurrence rate of target–lesion revascularization in the triple–therapy group (OR: 0.42, 95% CI: 0.26–0.69, P = 0.0005).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.